|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
After down-regulation of EGFR by siRNA in CRC cells, the effects of miR-141-3p on proliferation, migration and invasion were reversed. miR-141-3p played important roles in CRC growth and response to cetuximab treatment, and might function as a potential biomarker to predict cetuximab response.
|
31704502 |
2020 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus we propose that Wnt/β-catenin signals may be a downriver regulator in mediating the impacts of SNHG15 in CRC and SNHG15-miR-141-SIRT1 axis may pave a new sight in explaining the biological processes of CRC.
|
31213086 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>TP53, KRAS, APC</i>) has limited diagnostic sensitivity (40-60%), however, methylated DNA including <i>SEPT9, SFRP1, SDC2</i> can be applied with higher sensitivity (up to 90%) for CRC.Circulating miRNAs (e.g. miR-21, miR-92, miR-141) provide comparably high sensitivity for CRC as the circulating tumor cell mRNA markers (e.g.EGFR, CK19, CK20, CEA).
|
31046485 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the receiver operating characteristic (ROC) and area under the curve (AUC) were used to assess the diagnostic values of the miRNAs to discriminate cancerous from non-cancerous states of the samples.The expression levels of miR-30c, miR-144, miR-375, miR-214, and miR-195 in CRC tissue were significantly downregulated (all P < .05; Paired T-Test) than that in normal adjacent tissue sample (NATS), while the expression of miR-141, miR-182, miR-183, miR-21, and miR-370 in CRC tissue were significantly upregulated (all P < .001) than that in NATS.
|
31764853 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The biological roles of miR-141-3p in colorectal cancer were investigated both in vitro and a mouse model in vivo.
|
31078266 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pooled sensitivity and specificity of miR‑141 alone for CRC diagnosis were 82% and 75%, respectively.
|
29808805 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among these, blood miR141 and tissue miR224 were strong biomarkers of prognosis for CRC.
|
29750053 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, H19 activated the β-catenin pathway via acting as a competing endogenous RNA sponge for miR-141 in CRC, while miR-141 significantly inhibited the stemness of CRC cells.
|
30083271 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study suggests that targeting the miR-141-MAP2K4 signaling pathway may represent a novel approach for the treatment of CRC.
|
28454307 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that microRNA-141 (miR‑141) was downregulated in CSC compared with differentiated cancer cells, and in tumor compared with healthy tissue. miR‑141 may inhibit CRC cell proliferation and the maintenance of CSC stemness, thereby enhancing drug susceptibility.
|
28112364 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the role of miR‑200 and miR‑141 in the progression and liver metastasis of colorectal cancer in patients.
|
28944840 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was designed to determine the molecular function of miR-141 and the underlying mechanisms in colorectal cancer (CRC).
|
28739727 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, we propose four miRNAs (miR-96, miR-203, miR-141 and miR-200b) as clinically validated circulating biomarkers for CRC prognosis that warrant further evaluation for clinical utility.
|
26863633 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a miR real-time quantitative polymerase chain reaction (RT-qPCR), we observed that expression levels of miR-93, miR-195, and let-7b were significantly decreased, whereas those of miR-7, miR-141 and miR-494 showed increases that were more significant in the CRC tissue samples from the early relapsed patients than in those from the non-early relapsed patients.
|
27126129 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of preoperative levels of five fecal miRNAs, (miR-19-b-3p, miR-20a-5p, miR-21-3p, miR92a-3p, miR141) was significantly higher in CRC patients compared to controls and significantly decreased after curative surgery.
|
25989926 |
2015 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liver metastasis tissues showed higher expression of miR-200c (primary CRC = 1.31 vs. liver metastasis = 1.59; p = 0.0014) and miR-141 (primary CRC = 0.14 vs. liver metastasis = 0.17; p = 0.0234) than did primary CRCs, which was significantly associated with hypomethylation of the promoter region of these miRNAs (primary CRC = 61.2% vs. liver metastasis = 46.7%; p < 0.0001).
|
22735571 |
2013 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-141 regulates SIP1 to inhibit migration and invasion of CRC cells. miR-141 and SIP1 might be candidate therapeutic targets in CRC.
|
19830559 |
2010 |